請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/73251
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 鄭安理(Ann-Lii Cheng) | |
dc.contributor.author | I-Chun Chen | en |
dc.contributor.author | 陳怡君 | zh_TW |
dc.date.accessioned | 2021-06-17T07:24:42Z | - |
dc.date.available | 2024-08-27 | |
dc.date.copyright | 2019-08-27 | |
dc.date.issued | 2019 | |
dc.date.submitted | 2019-06-28 | |
dc.identifier.citation | Adams, S., Gray, R.J., Demaria, S., Goldstein, L., Perez, E.A., Shulman, L.N., Martino, S., Wang, M., Jones, V.E., Saphner, T.J., et al. (2014). Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 32, 2959-2966.
Adams, S., Loi, S., Toppmeyer, D., Cescon, D.W., De Laurentiis, M., Nanda, R., Winer, E.P., Mukai, H., Tamura, K., Armstrong, A., et al. (2019a). Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study. Annals of oncology : official journal of the European Society for Medical Oncology 30, 405-411. Adams, S., Schmid, P., Rugo, H.S., Winer, E.P., Loirat, D., Awada, A., Cescon, D.W., Iwata, H., Campone, M., Nanda, R., et al. (2019b). Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. Annals of oncology : official journal of the European Society for Medical Oncology 30, 397-404. Allred, D.C., Anderson, S.J., Paik, S., Wickerham, D.L., Nagtegaal, I.D., Swain, S.M., Mamounas, E.P., Julian, T.B., Geyer, C.E., Jr., Costantino, J.P., et al. (2012). Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 30, 1268-1273. Andre, F., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H.S., Iwata, H., Conte, P., Mayer, I.A., Kaufman, B., et al. (2019). Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. The New England journal of medicine 380, 1929-1940. Bachelot, T., Bourgier, C., Cropet, C., Ray-Coquard, I., Ferrero, J.M., Freyer, G., Abadie-Lacourtoisie, S., Eymard, J.C., Debled, M., Spaeth, D., et al. (2012). Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 30, 2718-2724. Bartsch, R., Bago-Horvath, Z., Berghoff, A., DeVries, C., Pluschnig, U., Dubsky, P., Rudas, M., Mader, R.M., Rottenfusser, A., Fitzal, F., et al. (2012). Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancer. European journal of cancer (Oxford, England : 1990) 48, 1932-1938. Baselga, J., Campone, M., Piccart, M., Burris, H.A., 3rd, Rugo, H.S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K.I., Lebrun, F., et al. (2012). Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. The New England journal of medicine 366, 520-529. Bianco, A.R., Rosso, R., Calabresi, F., Fiorentino, M., Lopez, M., Sismondi, P.G., Lenti, R., Fosser, V., De Placido, S., Perrone, F., et al. (1991). LH-RH analogue Zoladex in the treatment of pre- and perimenopausal women with metastatic breast cancer (results of the Italian Cooperative Study). European journal of gynaecological oncology 12, 429-437. Boccardo, F., Rubagotti, A., Perrotta, A., Amoroso, D., Balestrero, M., De Matteis, A., Zola, P., Sismondi, P., Francini, G., Petrioli, R., et al. (1994). Ovarian ablation versus goserelin with or without tamoxifen in pre-perimenopausal patients with advanced breast cancer: results of a multicentric Italian study. Annals of oncology : official journal of the European Society for Medical Oncology 5, 337-342. Bonneterre, J., Thurlimann, B., Robertson, J.F., Krzakowski, M., Mauriac, L., Koralewski, P., Vergote, I., Webster, A., Steinberg, M., and von Euler, M. (2000). Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 18, 3748-3757. Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D.R., Steins, M., Ready, N.E., Chow, L.Q., Vokes, E.E., Felip, E., Holgado, E., et al. (2015). Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. The New England journal of medicine 373, 1627-1639. Bosch, A., Li, Z., Bergamaschi, A., Ellis, H., Toska, E., Prat, A., Tao, J.J., Spratt, D.E., Viola-Villegas, N.T., Castel, P., et al. (2015). PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer. Science translational medicine 7, 283ra251. Brahmer, J.R., Drake, C.G., Wollner, I., Powderly, J.D., Picus, J., Sharfman, W.H., Stankevich, E., Pons, A., Salay, T.M., McMiller, T.L., et al. (2010). Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 28, 3167-3175. Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A., and Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians 68, 394-424. Buchanan, R.B., Blamey, R.W., Durrant, K.R., Howell, A., Paterson, A.G., Preece, P.E., Smith, D.C., Williams, C.J., and Wilson, R.G. (1986). A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 4, 1326-1330. Buzdar, A.U., Jones, S.E., Vogel, C.L., Wolter, J., Plourde, P., and Webster, A. (1997). A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group. Cancer 79, 730-739. Carlson, R.W., Theriault, R., Schurman, C.M., Rivera, E., Chung, C.T., Phan, S.C., Arun, B., Dice, K., Chiv, V.Y., Green, M., et al. (2010). Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 28, 3917-3921. Celio, L., Martinetti, A., Ferrari, L., Buzzoni, R., Mariani, L., Miceli, R., Seregni, E., Procopio, G., Cassata, A., Bombardieri, E., et al. (1999). Premenopausal breast cancer patients treated with a gonadotropin-releasing hormone analog alone or in combination with an aromatase inhibitor: a comparative endocrine study. Anticancer research 19, 2261-2268. Chen, M.J., Wu, W.Y., Yen, A.M., Fann, J.C., Chen, S.L., Chiu, S.Y., Chen, H.H., and Chiou, S.T. (2016). Body mass index and breast cancer: analysis of a nation-wide population-based prospective cohort study on 1 393 985 Taiwanese women. International journal of obesity (2005) 40, 524-530. Chou, T.C. (2010). Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer research 70, 440-446. Cole, M.P., Jones, C.T., and Todd, I.D. (1971). A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474. British journal of cancer 25, 270-275. Conte, C.C., Nemoto, T., Rosner, D., and Dao, T.L. (1989). Therapeutic oophorectomy in metastatic breast cancer. Cancer 64, 150-153. Correa, C., McGale, P., Taylor, C., Wang, Y., Clarke, M., Davies, C., Peto, R., Bijker, N., Solin, L., and Darby, S. (2010). Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. Journal of the National Cancer Institute Monographs 2010, 162-177. Curtis, C., Shah, S.P., Chin, S.F., Turashvili, G., Rueda, O.M., Dunning, M.J., Speed, D., Lynch, A.G., Samarajiwa, S., Yuan, Y., et al. (2012). The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486, 346-352. Dirix, L.Y., Takacs, I., Jerusalem, G., Nikolinakos, P., Arkenau, H.T., Forero-Torres, A., Boccia, R., Lippman, M.E., Somer, R., Smakal, M., et al. (2018). Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study. Breast cancer research and treatment 167, 671-686. Dunn, G.P., Old, L.J., and Schreiber, R.D. (2004). The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21, 137-148. Elston, C.W., and Ellis, I.O. (1991). Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19, 403-410. Falkson, C.I., Falkson, H.C., and Falkson, G. (1992). Cyclophosphamide, doxorubicin and fluorouracil (CAF) plus depo-buserelin in the treatment of premenopausal women with metastatic breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology 3, 849-853. Falkson, G., and Falkson, H.C. (1989). CAF and nasal buserelin in the treatment of premenopausal women with metastatic breast cancer. European journal of cancer & clinical oncology 25, 737-741. Falkson, G., Falkson, H.C., Glidewell, O., Weinberg, V., Leone, L., and Holland, J.F. (1979). Improved remission rates and remission duration in young women with metastatic breast cancer following combined oophorectomy and chemotherapy: a study of Cancer and Leukemia Groupe B. Cancer 43, 2215-2222. Falkson, G., Gelman, R.S., Leone, L., and Falkson, C.I. (1990). Survival of premenopausal women with metastatic breast cancer. Long-term follow-up of Eastern Cooperative Group and Cancer and Leukemia Group B studies. Cancer 66, 1621-1629. Falkson, G., Gelman, R.S., Tormey, D.C., Falkson, C.I., Wolter, J.M., and Cummings, F.J. (1987). Treatment of metastatic breast cancer in premenopausal women using CAF with or without oophorectomy: an Eastern Cooperative Oncology Group Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 5, 881-889. Falkson, G., Holcroft, C., Gelman, R.S., Tormey, D.C., Wolter, J.M., and Cummings, F.J. (1995). Ten-year follow-up study of premenopausal women with metastatic breast cancer: an Eastern Cooperative Oncology Group study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 13, 1453-1458. Fan, L., Strasser-Weippl, K., Li, J.J., St Louis, J., Finkelstein, D.M., Yu, K.D., Chen, W.Q., Shao, Z.M., and Goss, P.E. (2014). Breast cancer in China. The Lancet Oncology 15, e279-289. Forbes, J.F., Sestak, I., Howell, A., Bonanni, B., Bundred, N., Levy, C., von Minckwitz, G., Eiermann, W., Neven, P., Stierer, M., et al. (2016). Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial. Lancet (London, England) 387, 866-873. Forward, D.P., Cheung, K.L., Jackson, L., and Robertson, J.F. (2004). Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer. British journal of cancer 90, 590-594. Gil Del Alcazar, C.R., Huh, S.J., Ekram, M.B., Trinh, A., Liu, L.L., Beca, F., Zi, X., Kwak, M., Bergholtz, H., Su, Y., et al. (2017). Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition. Cancer discovery 7, 1098-1115. Harris, L.N., Ismaila, N., McShane, L.M., Andre, F., Collyar, D.E., Gonzalez-Angulo, A.M., Hammond, E.H., Kuderer, N.M., Liu, M.C., Mennel, R.G., et al. (2016). Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 34, 1134-1150. Hendry, S., Salgado, R., Gevaert, T., Russell, P.A., John, T., Thapa, B., Christie, M., van de Vijver, K., Estrada, M.V., Gonzalez-Ericsson, P.I., et al. (2017). Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. Advances in anatomic pathology 24, 235-251. Heuson, J.C. (1976). Current overview of EORTC clinical trials with tamoxifen. Cancer treatment reports 60, 1463-1466. Hodi, F.S., O'Day, S.J., McDermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J.C., et al. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. The New England journal of medicine 363, 711-723. Hoogstraten, B., Fletcher, W.S., Gad-el-Mawla, N., Maloney, T., Altman, S.J., Vaughn, C.B., and Foulkes, M.A. (1982). Tamoxifen and oophorectomy in the treatment of recurrent breast cancer: a Southwest Oncology Group Study. Cancer research 42, 4788-4791. Hoogstraten, B., Gad-el-Mawla, N., Maloney, T.R., Fletcher, W.S., Vaughn, C.B., Tranum, B.L., Athens, J.W., Costanzi, J.J., and Foulkes, M. (1984). Combined modality therapy for first recurrence of breast cancer. A Southwest Oncology Group study. Cancer 54, 2248-2256. Hortobagyi, G.N., Chen, D., Piccart, M., Rugo, H.S., Burris, H.A., 3rd, Pritchard, K.I., Campone, M., Noguchi, S., Perez, A.T., Deleu, I., et al. (2016). Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 34, 419-426. Im, S.A., Lu, Y.S., Bardia, A., Harbeck, N., Colleoni, M., Franke, F., Chow, L., Sohn, J., Lee, K.S., Campos-Gomez, S., et al. (2019). Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. The New England journal of medicine. Ingle, J.N., Krook, J.E., Green, S.J., Kubista, T.P., Everson, L.K., Ahmann, D.L., Chang, M.N., Bisel, H.F., Windschitl, H.E., Twito, D.I., et al. (1986). Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 4, 178-185. Ingle, J.N., Suman, V.J., Rowland, K.M., Mirchandani, D., Bernath, A.M., Camoriano, J.K., Fishkin, P.A., Nikcevich, D.A., and Perez, E.A. (2006). Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 24, 1052-1056. Ishida, Y., Agata, Y., Shibahara, K., and Honjo, T. (1992). Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. The EMBO journal 11, 3887-3895. Jensen, E.V., and DeSombre, E.R. (1973). Estrogen-receptor interaction. Science (New York, NY) 182, 126-134. Jonat, W., Kaufmann, M., Blamey, R.W., Howell, A., Collins, J.P., Coates, A., Eiermann, W., Janicke, F., Njordenskold, B., Forbes, J.F., et al. (1995). A randomised study to compare the effect of the luteinising hormone releasing hormone (LHRH) analogue goserelin with or without tamoxifen in pre- and perimenopausal patients with advanced breast cancer. European journal of cancer (Oxford, England : 1990) 31a, 137-142. Jordan, V.C. (1995). Third annual William L. McGuire Memorial Lecture. 'Studies on the estrogen receptor in breast cancer'--20 years as a target for the treatment and prevention of cancer. Breast cancer research and treatment 36, 267-285. Jung, D., and Lee, S.M. (2009). BMI and Breast Cancer in Korean Women: A Meta-Analysis. Asian nursing research 3, 31-40. Katzenellenbogen, B.S., Miller, M.A., Mullick, A., and Sheen, Y.Y. (1985). Antiestrogen action in breast cancer cells: modulation of proliferation and protein synthesis, and interaction with estrogen receptors and additional antiestrogen binding sites. Breast cancer research and treatment 5, 231-243. Kaufmann, M., Bajetta, E., Dirix, L.Y., Fein, L.E., Jones, S.E., Cervek, J., Fowst, C., Polli, A., Di Salle, E., Massimini, G., et al. (2000). Exemestane improves survival compared with megoestrol acetate in postmenopausal patients with advanced breast cancer who have failed on tamoxifen. results Of a double-blind randomised phase III trial. European journal of cancer (Oxford, England : 1990) 36 Suppl 4, S86-87. Kaufmann, M., Jonat, W., Kleeberg, U., Eiermann, W., Janicke, F., Hilfrich, J., Kreienberg, R., Albrecht, M., Weitzel, H.K., Schmid, H., et al. (1989). Goserelin, a depot gonadotrophin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. German Zoladex Trial Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 7, 1113-1119. Klijn, J.G., Beex, L.V., Mauriac, L., van Zijl, J.A., Veyret, C., Wildiers, J., Jassem, J., Piccart, M., Burghouts, J., Becquart, D., et al. (2000). Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study. Journal of the National Cancer Institute 92, 903-911. Klijn, J.G., de Jong, F.H., Blankenstein, M.A., Docter, R., Alexieva-Figusch, J., Blonk-van der Wijst, J., and Lamberts, S.W. (1984). Anti-tumor and endocrine effects of chronic LHRH agonist treatment (Buserelin) with or without tamoxifen in premenopausal metastatic breast cancer. Breast cancer research and treatment 4, 209-220. Kuo, S.H., Lo, C., Chen, Y.H., Lien, H.C., Kuo, W.H., Wang, M.Y., Lee, Y.H., and Huang, C.S. (2018). Prognostic Significance of Clinicopathologic Features in Patients With Breast Ductal Carcinoma-in-Situ Who Received Breast-Conserving Surgery. Clinical breast cancer 18, 441-450.e442. Lakhani, S.R., Ellis. I.O., Schnitt, S.J., Tan, P.H., van de Vijver, M.J (2012). WHO Classification of Tumours of the Breast, 4 edn. Le, D.T., Durham, J.N., Smith, K.N., Wang, H., Bartlett, B.R., Aulakh, L.K., Lu, S., Kemberling, H., Wilt, C., Luber, B.S., et al. (2017). Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science (New York, NY) 357, 409-413. Le, D.T., Uram, J.N., Wang, H., Bartlett, B.R., Kemberling, H., Eyring, A.D., Skora, A.D., Luber, B.S., Azad, N.S., Laheru, D., et al. (2015). PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. The New England journal of medicine 372, 2509-2520. Leach, D.R., Krummel, M.F., and Allison, J.P. (1996). Enhancement of antitumor immunity by CTLA-4 blockade. Science (New York, NY) 271, 1734-1736. Lehmann, B.D., Bauer, J.A., Chen, X., Sanders, M.E., Chakravarthy, A.B., Shyr, Y., and Pietenpol, J.A. (2011). Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. The Journal of clinical investigation 121, 2750-2767. Liao, S., Hartmaier, R.J., McGuire, K.P., Puhalla, S.L., Luthra, S., Chandran, U.R., Ma, T., Bhargava, R., Modugno, F., Davidson, N.E., et al. (2015). The molecular landscape of premenopausal breast cancer. Breast cancer research : BCR 17, 104. Lin, C.H., Chuang, P.Y., Chiang, C.J., Lu, Y.S., Cheng, A.L., Kuo, W.H., Huang, C.S., Lai, M.S., You, S.L., and Tang, C.H. (2014). Distinct clinicopathological features and prognosis of emerging young-female breast cancer in an East Asian country: a nationwide cancer registry-based study. The oncologist 19, 583-591. Lin, C.H., Liau, J.Y., Lu, Y.S., Huang, C.S., Lee, W.C., Kuo, K.T., Shen, Y.C., Kuo, S.H., Lan, C., Liu, J.M., et al. (2009). Molecular subtypes of breast cancer emerging in young women in Taiwan: evidence for more than just westernization as a reason for the disease in Asia. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 18, 1807-1814. Lin, C.H., Yap, Y.S., Lee, K.H., Im, S.A., Naito, Y., Yeo, W., Ueno, T., Kwong, A., Li, H., Huang, S.M., et al. (2019). Contrasting Epidemiology and Clinicopathology of Female Breast Cancer in Asians versus the US Population. Journal of the National Cancer Institute. Llombart-Cussac, A., Ruiz, A., Anton, A., Barnadas, A., Antolin, S., Ales-Martinez, J.E., Alvarez, I., Andres, R., Garcia Saenz, J.A., Lao, J., et al. (2012). Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer: final results from the Spanish Breast Cancer Group 2001-03 phase 2 randomized trial. Cancer 118, 241-247. Loibl, S., Turner, N.C., Ro, J., Cristofanilli, M., Iwata, H., Im, S.A., Masuda, N., Loi, S., Andre, F., Harbeck, N., et al. (2017). Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results. The oncologist 22, 1028-1038. Manni, A., and Pearson, O.H. (1980). Antiestrogen-induced remissions in premenopausal women with stage IV breast cancer: effects on ovarian function. Cancer treatment reports 64, 779-785. Margreiter, R., and Wiegele, J. (1984). Tamoxifen (Nolvadex) for premenopausal patients with advanced breast cancer. Breast cancer research and treatment 4, 45-48. Matsuno, R.K., Anderson, W.F., Yamamoto, S., Tsukuma, H., Pfeiffer, R.M., Kobayashi, K., Devesa, S.S., and Levine, P.H. (2007). Early- and late-onset breast cancer types among women in the United States and Japan. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 16, 1437-1442. McGranahan, N., and Swanton, C. (2017). Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future. Cell 168, 613-628. MINORU YOSHIDA, H.M., MIURA SHIGETO (1982). Tamoxifen Therapy for Premenopausal and Postmenopausal Japanese Females with Advanced Breast Cancer Japanese Journal of Clinical Oncology 12, 57. Motzer, R.J., Rini, B.I., McDermott, D.F., Redman, B.G., Kuzel, T.M., Harrison, M.R., Vaishampayan, U.N., Drabkin, H.A., George, S., Logan, T.F., et al. (2015). Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 33, 1430-1437. Mouridsen, H., Gershanovich, M., Sun, Y., Perez-Carrion, R., Boni, C., Monnier, A., Apffelstaedt, J., Smith, R., Sleeboom, H.P., Janicke, F., et al. (2001). Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 19, 2596-2606. Nanda, R., Chow, L.Q., Dees, E.C., Berger, R., Gupta, S., Geva, R., Pusztai, L., Pathiraja, K., Aktan, G., Cheng, J.D., et al. (2016). Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 34, 2460-2467. Newman, A.M., Liu, C.L., Green, M.R., Gentles, A.J., Feng, W., Xu, Y., Hoang, C.D., Diehn, M., and Alizadeh, A.A. (2015). Robust enumeration of cell subsets from tissue expression profiles. Nature methods 12, 453-457. Nishimura, R., Anan, K., Yamamoto, Y., Higaki, K., Tanaka, M., Shibuta, K., Sagara, Y., Ohno, S., Tsuyuki, S., Mase, T., et al. (2013). Efficacy of goserelin plus anastrozole in premenopausal women with advanced or recurrent breast cancer refractory to an LH-RH analogue with tamoxifen: results of the JMTO BC08-01 phase II trial. Oncology reports 29, 1707-1713. Ock, C.Y., Hwang, J.E., Keam, B., Kim, S.B., Shim, J.J., Jang, H.J., Park, S., Sohn, B.H., Cha, M., Ajani, J.A., et al. (2017). Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers. Nature communications 8, 1050. Pages, F., Mlecnik, B., Marliot, F., Bindea, G., Ou, F.S., Bifulco, C., Lugli, A., Zlobec, I., Rau, T.T., Berger, M.D., et al. (2018). International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet (London, England) 391, 2128-2139. Park, I.H., Ro, J., Lee, K.S., Kim, E.A., Kwon, Y., Nam, B.H., Jung, S.Y., Lee, S., Kim, S.W., and Kang, H.S. (2010). Phase II parallel group study showing comparable efficacy between premenopausal metastatic breast cancer patients treated with letrozole plus goserelin and postmenopausal patients treated with letrozole alone as first-line hormone therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 28, 2705-2711. Perou, C.M., Sorlie, T., Eisen, M.B., van de Rijn, M., Jeffrey, S.S., Rees, C.A., Pollack, J.R., Ross, D.T., Johnsen, H., Akslen, L.A., et al. (2000). Molecular portraits of human breast tumours. Nature 406, 747-752. Planting, A.S., Alexieva-Figusch, J., Blonk-vdWijst, J., and van Putten, W.L. (1985). Tamoxifen therapy in premenopausal women with metastatic breast cancer. Cancer treatment reports 69, 363-368. Pritchard, K.I., Thomson, D.B., Myers, R.E., Sutherland, D.J., Mobbs, B.G., and Meakin, J.W. (1980). Tamoxifen therapy in premenopausal patients with metastatic breast cancer. Cancer treatment reports 64, 787-796. Quail, D.F., Olson, O.C., Bhardwaj, P., Walsh, L.A., Akkari, L., Quick, M.L., Chen, I.C., Wendel, N., Ben-Chetrit, N., Walker, J., et al. (2017). Obesity alters the lung myeloid cell landscape to enhance breast cancer metastasis through IL5 and GM-CSF. Nature cell biology 19, 974-987. Rizvi, N.A., Hellmann, M.D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J.J., Lee, W., Yuan, J., Wong, P., Ho, T.S., et al. (2015). Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science (New York, NY) 348, 124-128. Rossof, A.H., Gelman, R., and Creech, R.H. (1982). Randomized evaluation of combination chemotherapy vs. observation alone following response or stabilization after oophorectomy for metastatic breast cancer in premenopausal women. American journal of clinical oncology 5, 253-259. Rugo, H.S., Delord, J.P., Im, S.A., Ott, P.A., Piha-Paul, S.A., Bedard, P.L., Sachdev, J., Tourneau, C.L., van Brummelen, E.M.J., Varga, A., et al. (2018). Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 24, 2804-2811. Sabine, V.S., Crozier, C., Brookes, C.L., Drake, C., Piper, T., van de Velde, C.J., Hasenburg, A., Kieback, D.G., Markopoulos, C., Dirix, L., et al. (2014). Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 32, 2951-2958. Sawka, C.A., Pritchard, K.I., Shelley, W., DeBoer, G., Paterson, A.H., Meakin, J.W., and Sutherland, D.J. (1997). A randomized crossover trial of tamoxifen versus ovarian ablation for metastatic breast cancer in premenopausal women: a report of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial MA.1. Breast cancer research and treatment 44, 211-215. Schmid, P., Adams, S., Rugo, H.S., Schneeweiss, A., Barrios, C.H., Iwata, H., Dieras, V., Hegg, R., Im, S.A., Shaw Wright, G., et al. (2018). Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. The New England journal of medicine 379, 2108-2121. Silverstein, M.J., Lagios, M.D., Craig, P.H., Waisman, J.R., Lewinsky, B.S., Colburn, W.J., and Poller, D.N. (1996). A prognostic index for ductal carcinoma in situ of the breast. Cancer 77, 2267-2274. Sinn, H.P., and Kreipe, H. (2013). A Brief Overview of the WHO Classification of Breast Tumors, 4th Edition, Focusing on Issues and Updates from the 3rd Edition. Breast care (Basel, Switzerland) 8, 149-154. Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J.M., Desrichard, A., Walsh, L.A., Postow, M.A., Wong, P., Ho, T.S., et al. (2014). Genetic basis for clinical response to CTLA-4 blockade in melanoma. The New England journal of medicine 371, 2189-2199. Suh, K.J., Kim, S.H., Lee, K.H., Kim, T.Y., Kim, Y.J., Han, S.W., Kang, E., Kim, E.K., Kim, K., No, J.H., et al. (2017). Bilateral Salpingo-oophorectomy Compared to Gonadotropin-Releasing Hormone Agonists in Premenopausal Hormone Receptor-Positive Metastatic Breast Cancer Patients Treated with Aromatase Inhibitors. Cancer research and treatment : official journal of Korean Cancer Association 49, 1153-1163. Svoronos, N., Perales-Puchalt, A., Allegrezza, M.J., Rutkowski, M.R., Payne, K.K., Tesone, A.J., Nguyen, J.M., Curiel, T.J., Cadungog, M.G., Singhal, S., et al. (2017). Tumor Cell-Independent Estrogen Signaling Drives Disease Progression through Mobilization of Myeloid-Derived Suppressor Cells. Cancer discovery 7, 72-85. Tanaka, K., Tokunaga, E., Yamashita, N., Taketani, K., Akiyoshi, S., Morita, M., and Maehara, Y. (2014). Luteinizing hormone-releasing hormone agonist plus an aromatase inhibitor as second-line endocrine therapy in premenopausal females with hormone receptor-positive metastatic breast cancer. Surgery today 44, 1678-1684. Taylor, C.W., Green, S., Dalton, W.S., Martino, S., Rector, D., Ingle, J.N., Robert, N.J., Budd, G.T., Paradelo, J.C., Natale, R.B., et al. (1998). Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 16, 994-999. Topalian, S.L., Hodi, F.S., Brahmer, J.R., Gettinger, S.N., Smith, D.C., McDermott, D.F., Powderly, J.D., Carvajal, R.D., Sosman, J.A., Atkins, M.B., et al. (2012). Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. The New England journal of medicine 366, 2443-2454. Torrisi, R., Bagnardi, V., Pruneri, G., Ghisini, R., Bottiglieri, L., Magni, E., Veronesi, P., D'Alessandro, C., Luini, A., Dellapasqua, S., et al. (2007). Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer. British journal of cancer 97, 802-808. Treilleux, I., Arnedos, M., Cropet, C., Wang, Q., Ferrero, J.M., Abadie-Lacourtoisie, S., Levy, C., Legouffe, E., Lortholary, A., Pujade-Lauraine, E., et al. (2015). Translational studies within the TAMRAD randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology 26, 120-125. Tripathy, D., Im, S.A., Colleoni, M., Franke, F., Bardia, A., Harbeck, N., Hurvitz, S.A., Chow, L., Sohn, J., Lee, K.S., et al. (2018). Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. The Lancet Oncology 19, 904-915. Wada, T., Koyama, H., and Terasawa, T. (1981). Effect of tamoxifen in premenopausal Japanese women with advanced breast cancer. Cancer treatment reports 65, 728-729. Wang, J., Xu, B., Yuan, P., Ma, F., Li, Q., Zhang, P., Cai, R., Fan, Y., Luo, Y | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/73251 | - |
dc.description.abstract | 乳癌近三十年在台灣與東亞地區快速增加,然而其好發年齡、病理型態、分子分類及病人癒後都與西方國家不同,主要為停經前婦女,並且以荷爾蒙受體陽性的類型為主,其發生原因至今仍然不清楚。荷爾蒙受體陽性的乳癌病人,其荷爾蒙用藥,近四十年主要有tamoxifen及aromatase inhibitors;針對停經前婦女在這四十年間,主要的用藥僅有tamoxifen,並無太多進展。東亞地區主要是停經前荷爾蒙受體陽性的乳癌為最多,這方面的研究在歐美非常鮮少。尋找優化現有荷爾蒙治療用藥,改善荷爾蒙受體陽性乳癌病人治療成績,尤其是停經前婦女的治療,是我們亟待解決的問題。
本研究主軸是以優化停經前荷爾蒙受體陽性乳癌的荷爾蒙治療為出發,由臨床前期實驗,銜接到臨床試驗。第一部份是mTOR抑制劑與荷爾蒙治療併用相關的biomarker,以了解是否亞洲病人適用此治療方式,第二部分是PI3K抑制劑與荷爾蒙治療併用的臨床前期實驗與臨床試驗,第三部分是以荷爾蒙治療與免疫抑制劑併用的臨床試驗設計,實際針對停經前荷爾蒙受體陽性乳癌的新治療注入活水。 (1)以荷爾蒙治療併用mTOR抑制劑: PIK3CA乃荷爾蒙受體陽性乳癌最常見的突變之一,且BOLERO-2的成功亦暗示了,荷爾蒙治療藥物併用PI3K/AKT/mTOR路徑上的抑制劑,是一個可行的治療方向。同一時期TAMRAD試驗的結果,在biomarker的分析中,發現當tamoxifen併用everolimus時,LKB1可能可以預測療效。在BOLERO-2與TAMRAD兩個臨床試驗案,僅納入停經後婦女;而對於在東亞我們面對的,主要是停經前荷爾蒙受體陽性的乳癌病人,tamoxifen是主要的治療藥物選擇,是故,若在停經後婦女有效果,我們認為也許在停經前婦女的荷爾蒙受體陽性乳癌,tamoxifen併用Everolimus可能也會有角色,因此我們一方面展開了LKB1在亞洲乳癌預後角色的translational study,一方面想尋求是否有機會領導tamoxifen併用everolimus在亞洲停經前荷爾蒙受體陽性乳癌的臨床試驗。 LKB1本身是AMPK的上游蛋白質,在腫瘤發生過程中,是一個腫瘤抑制基因。在TAMRAD試驗的分析中,低的LKB1表現量,可以預測everolimus的藥效。我分析了台大、馬偕檢體的LKB1免疫染色,與英國兩個METABRIC datasets基因表現量的資料,主要想探討LKB1在停經前乳癌病人的角色。LKB1在我的研究中發現,與荷爾蒙受體的表現有高度相關,然而對於整體存活率來說,只有在HER2陽性的病人族群, LKB1的表現量才與OS有關。原先進行這個translational study的初衷,是希望對於everolimus併用Tamoxifen是否可能在亞洲的停經前荷爾蒙受體陽性乳癌有效,做一些評估。雖然後續因為everolimus在藥廠並沒有進一步進行臨床試驗的意願,同時我們的細胞實驗發現,eveolimus/tamoxifen僅有additive效果,不如PI3K抑制劑和tamoxifen併用時,是synergistic效果,我們沒有繼續以everolimus/ tamoxifen的組合往下做研究延伸,轉而以PI3K抑制劑與tamoxifen的組合進行臨床前與臨床試驗發展。 (2) 以荷爾蒙治療併用PI3K抑制劑: PIK3CA是荷爾蒙受體陽性乳癌最常見的突變,而且由everolimus的成功推測,若以PI3K抑制劑併用荷爾蒙治療,可能亦有機會強化荷爾蒙治療在荷爾蒙受體陽性乳癌的效果。本研究的第二個研究子題,乃環繞PI3K抑制劑併用tamoxifen的臨床試驗設計與臨床前期研究。身為腫瘤內科醫師,對於藥物發展除了臨床前期研究的支持外,另一個重要的環節,在於臨床試驗的設計與執行,本人參與設計了B-YOND 臨床試驗。此Phase Ib的試驗案,我們主要收納停經前荷爾蒙受體陽性乳癌病人,測試在第一線荷爾蒙治療使用tamoxifen時,併用buparlisib或是alpelisib的治療效果,並且尋找出後續在Phase II時的,最大耐受劑量。 在此臨床試驗的設計過程中,除了對於亞洲停經前荷爾蒙陽性乳癌病人更加了解外,同時對於估計藥物效果與副作用,以有意義的統計假設進行設計,對於臨床試驗執行面的了解,包括與Sponsor的溝通、經費的取得、整體預算的編列,追蹤病人給藥各方面,有更全面的學習。目前初步的分析仍在進行中,預計在2019年年底會有正式的研究成果發表。而根據SOLAR-1臨床試驗在停經後婦女的結果,PI3K抑制劑併用tamoxifen/goserelin在停經前婦女預期也會有不錯的效果。 另一方面,本研究主要以細胞實驗與動物實驗,來確認PI3K廣泛型抑制劑buparlisib與PI3K-alpha專一型抑制劑alpelisib,和tamoxifen併用的效果與機轉,以對B-YOND臨床試驗提供更多可能會有效的證據。 首先以具有不同PI3K/AKT途徑上突變的荷爾蒙受體陽性乳癌細胞株進行實驗,以MTT活性存活測試,並計算藥物合併指數(combination index),用來比較併用藥物時的效果。buparlisib或alpelisib與tamoxifen併用,其藥物合併指數皆小於1,表示皆有加乘效果。此加乘不只侷限在PI3K/AKT路徑有突變的細胞株。進一步發現MCF-7和ZR75-1細胞株接受Buparlisib或Alpelisib與Tamoxifen併用後,細胞停留在SubG1的比例會高於單用tamoxifen、buparlisib或是alpelisib。以Annexin-V與PI進行染色時可發現,tamoxifen併用buparlisib或alpelisib的細胞,會增加Annexin-V+/PI+的細胞比例,表示這些藥物治療,主要是透過apoptosis死亡;西方墨點法分析接受上述藥物治療的細胞蛋白質時,可發現同時會透過降低磷酸化的4EBP1,磷酸化的GSK3β,磷酸化的p70S6K,來影響下游的訊息傳導。 為了證明上述tamoxifen併用buparlisib或alpelisib,主要透過哪個路徑影響藥物效果,我們以MCF-7細胞株當作對照組,一組MCF-7細胞株轉殖了mock,一組MCF-7細胞株轉殖了AKT,此乃為了強迫AKT的表現。AKT會一直表現的MCF-7細胞,在接受了tamoxifen併用buparlisib或alpelisib時,藥物合併指數會大於一,表示原本的加乘效果消失。且其下游的磷酸化的4EBP1,磷酸化的GSK3β,磷酸化的p70S6K,亦不受到抑制。另一方面,我們想比較是否荷爾蒙受體在tamoxifen併用buparlisib或alpelisib時,具有角色。是故我們將MCF-7細胞株與ZR-75-1細胞株轉殖了具有Y537S突變的荷爾蒙受體,並且分別以tamoxifen併用buparlisib或alpelisib進行比較。當細胞具有Y537S突變的荷爾蒙受體時,則藥物合併指數亦大於一,表示原先的加乘效果也消失了。上述兩組實驗證實了,tamoxifen併用buparlisib或alpelisib的加乘效果,需仰賴正常的AKT與無突變的荷爾蒙受體。 基於細胞實驗的結果,本研究進一步進行裸鼠動物實驗。tamoxifen併用buparlisib或alpelisib用以治療裸鼠的MCF-7腫瘤實驗中,buparlisib或alpelisib併用tamoxifen,相較於對照組或是單用tamoxifen、buparlisib或alpelisib的組別,皆讓MCF-7的腫瘤生長變慢,小鼠有較長的存活。我們取下裸鼠的MCF-7腫瘤,進行免疫染色分析,發現與前述的MCF-7細胞株在西方墨點法分析的結果相近,buparlisib或alpelisib併用tamoxifen會降低磷酸化的Akt,磷酸化的S6,磷酸化的p70S6K。 (3)荷爾蒙治療併用免疫治療的臨床試驗設計 有鑑於本研究中亞洲的乳癌病人有不少具有慢性發炎的特性,同時發現亞洲女性荷爾蒙受體陽性乳癌中,管腔B型為多,而且具有較高的免疫反應性,是故本研究的假說是,以免疫治療並用荷爾蒙治療,會有不錯的療效。本人參與了PEER臨床試驗的設計與計畫書的撰寫,並且負責病人檢體translation study,以找出療效預測因子。PEER納入停經前荷爾蒙陽性乳癌,未曾接受過化學治療者,給予荷爾蒙治療exemestane/ leuprolide,併用免疫治療pembrolizumab。本人亦同時在發展免疫健全小鼠的乳癌模式,預備進一步探討荷爾蒙治療併用免疫治療的機轉。目前臨床試驗還在收案中,但是可評估的十一位病人當中,有四位達到部分緩解,並且持續有效中。不僅這是在第二或第三線已經對荷爾蒙治療產生抗藥性的狀態下,很突出的治療效果。同時,也是少數在荷爾蒙陽性停經前乳癌病人,接受免疫治療,能夠有這麼高的反應率的組合。 整體而言,本研究內容,針對如何優化停經前荷爾蒙受體陽性乳癌的荷爾蒙治療,由PI3K/mTOR路徑的抑制劑與荷爾蒙治療併用,或是近期仍持續進行中的免疫治療與荷爾蒙治療併用。不管是以臨床前期的細胞或動物模式,來證實荷爾蒙治療併用PI3K抑制劑的效果與機轉,同時支持PI3K抑制劑併用荷爾蒙治療;或是仍在進行中的荷爾蒙陽性乳癌在免疫健全小鼠的實驗模式,進一步了解免疫治療與荷爾蒙治療併用的有效機轉,並且同時進行臨床試驗與病人檢體的研究。針對東亞主要的停經前荷爾蒙受體陽性的乳癌病人,我們的研究方向逐漸可以讓這群病人的治療,再往前邁進一步。 | zh_TW |
dc.description.abstract | Breast cancer has emerged rapidly in Taiwan and East Asia in recent 3 decades. The age distribution, pathologic features, molecular subtypes, and patient prognosis of breast cancer patients in East Asia are all very different from those in western countries. The majority of breast cancer patients in East Asia is premenopausal and estrogen receptor positive. The etiology of this emerging breast cancer is still unknown.
For estrogen receptor positive breast cancer patients, hormonal therapy developed in the past 40 years are tamoxifen, aromatase inhibitors, and fulvestrant. As for hormonal therapy specific for premenopausal patients, tamoxifen is the only drug in the past 40 years. Premenopausal breast cancer patients are endemic in East Asia, but not in western countries. Therefore, the research focusing on premenopausal breast cancer patients is not popular in western countries. Optimizing current hormonal therapy to improve treatment results in premenopausal hormonal receptor positive breast cancer patients is an unmet medical need. The main focus of this research is to optimize the hormonal therapy for premenopausal estrogen receptor positive breast cancer patients. We started from preclinical experiments to clinical trials. The first part of the study, I investigated the biomarker from mTOR inhibitor and tamoxifen combination. I would like to understand if this combination is feasible for Asian patients or not. The second part of the study is the combination of PI3K inhibitor and hormonal therapy in preclinical experiments and clinical trials. The last part is hormonal therapy in combination with immunotherapy in a clinical trial setting. (A)Hormonal therapy and mTOR inhibitor PIK3CA mutation is one of the most common mutations in estrogen receptor positive breast cancer. The success from BOLERO-2 trial also suggests that combining hormonal therapy and PI3K/AKT/mTOR inhibitors is a feasible treatment strategy. At the same time, biomarker study from TAMRAD trial discovered LKB1 as a potential efficacy predictor for everolimus in combination with tamoxifen. However, in BOLERO-2 and TAMRAD study, they only enrolled postmenopausal women. We wondered if tamoxifen and everolimus would also be effective for premenopausal patients in East Asia. Therefore, we started from understanding the role of LKB1 in Asian breast cancer patients and hoping to have a chance leading tamoxifen/ everolimus clinical trials in premenopausal patients in Asia. I have analyzed the tumor slides from National Taiwan University Hospital and Mackay Memorial Hospital by LKB1 immunohistochemical staining and gene expression levels from the two METABRIC datasets. The aim is to understand the role of LKB1 in premenopausal estrogen receptor positive breast cancer. However, LKB1 is associated with estrogen receptor positivity, but not prognosis. It was only in the HER-2 positive group that LKB1 is prognostic for overall survival. Despite our hypothesis was LKB1 might play an important role in estrogen receptor positive breast cancer, the result did not support this hypothesis. On the other hand, the pharmaceutical companies also do not plan to further invest on everolimus. We then moved to another target, PI3K, on the same thread. (B)Hormonal therapy and PI3K inhibitor We aim to investigate if PI3K inhibitor is a good partner to enhance hormonal therapy efficacy in estrogen receptor positive breast cancer. We utilized human breast cancer cell lines harboring different PI3K pathway alterations to demonstrate a synergistic effect between tamoxifen and PI3K inhibitor. I used siRNA to silence PIK3CA, myristoylated AKT to constantly activate AKT, and mutant estrogen receptor transfection to mitigate estrogen receptor function. These strategies demonstrate that the synergistic effect of tamoxifen and PI3K inhibitor rely on AKT, PIK3CA, and functioning estrogen receptor. Furthermore, MCF-7 xenograft treated with tamoxifen and PI3K inhibitor also demonstrated tumor shrinkage. This suggests the rationale to support the design of clinical trial, B-YOND. We have enrolled patients into either tamoxifen/ goserelin/ alpelisib or buparlisib. (C)Hormonal therapy and immunotherapy Chronic inflammation is a common characteristic in Asian breast cancer patients. Luminal B subtype, which is more immunoreactive, is enriched in Asian breast cancer patients. We hypothesize that combining hormonal therapy and immunotherapy would be efficacious in Asian breast cancer patients. I have designed the PEER clinical trial and translational studies with Professor Lu. In this study, we enrolled premenopausal estrogen receptor positive breast cancer patients, who had not received chemotherapy for metastatic disease. Hormonal therapy (exemestane and leuprolide), and immunotherapy (pembrolizumab) were given together in this study. Among the 11 evaluable patients, 4 patients achieved a partial response. This extraordinary response is superior to usual response rates in the 2nd line and 3rd line of hormonal therapy in estrogen receptor positive breast cancer patients. I am also working on establishing an immunocompetent estrogen receptor positive murine model to study the mechanism underlying this combination therapy. In conclusion, my study helps to understand the mechanism of hormonal therapy in combination with targeted therapy or immunotherapy. We have provided evidence from preclinical investigations to consolidate the ideas before moving into clinical trials. This is a very good training for me as a medical oncologist working from bench to bedside and backwards. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T07:24:42Z (GMT). No. of bitstreams: 1 ntu-108-D02453003-1.pdf: 4139908 bytes, checksum: a89dd234282e2d2bbdfa0a6f222b56af (MD5) Previous issue date: 2019 | en |
dc.description.tableofcontents | 目錄
口試委員會審定書 誌謝 中文摘要 i 英文摘要 iv 第一章 緒論 1 1 引言 1 1.1 乳腺原位癌 1 1.2 乳房癌症 2 1.3 荷爾蒙治療的進展 6 第二章 研究材料 12 2 研究材料: 12 2.1 細胞株: 12 2.2 小鼠: 12 2.3 藥品與試劑: 12 2.4 乳癌病人檢體 13 2.5 METABRIC資料組 13 第三章 研究方法 14 3 研究方法: 14 3.1 MTT 分析法: 14 3.2 藥物合併指數:Combination index (C.I.) 14 3.3 西方墨點法 15 3.4 流式細胞儀 15 3.5 腫瘤生長與治療 16 3.6 免疫組織化學染色 17 3.7 基因轉染 18 第四章 結果 19 4 研究結果: 19 4.1 以荷爾蒙治療併用mTOR抑制劑: 19 4.2 以荷爾蒙治療併用PI3K抑制劑: 22 4.3 以荷爾蒙治療併用免疫治療: 28 第五章 結論 37 5 結論 37 5.1 以荷爾蒙治療併用mTOR抑制劑 37 5.2 以荷爾蒙治療併用PI3K抑制劑 38 5.3 以荷爾蒙治療併用免疫治療 40 第六章 展望 42 6 未來展望 42 6.1 本研究對於優化荷爾蒙治療在荷爾蒙受體陽性乳癌的重要性 42 6.2 未來的研究方向 43 參考資料 46 圖一:LKB1免疫組織化學染色分級: 65 圖二:整體存活分析 66 圖三:台大醫院與馬偕醫院病人整體存活分析: 67 圖四:藥物併用指數 68 圖五:PI3K下游訊息傳導變化:治療後三小時、八小時、二十四小時 69 圖六:細胞週期與細胞凋亡 70 圖七:使用不同PI3K subunit的小型抑制性RNA 71 圖八:過度表現AKT分子之MCF-7細胞株與藥物併用實驗 72 圖九:藥物併用指數:對tamoxifen有抗藥性的MCF-7細胞株 73 圖十:MCF-7腫瘤大小 74 圖十一:MCF-7腫瘤蠟塊切片免疫組織化學染色分析 75 圖十二:PEER臨床試驗案設計 76 圖十三:達到部分緩解的三位病人:指標病灶變化 77 圖十四:腫瘤未惡化存活期 78 圖十五:治療前荷爾蒙受體陽性比例與腫瘤未惡化存活期的關係 79 圖十六:小鼠乳癌細胞株的基因表現量 80 圖十七:99LN腫瘤生長速度 81 圖十八:流式細胞儀分析99LN腫瘤內浸潤免疫細胞族群 82 圖十九:99LN小鼠實驗(AKT抑制劑、荷爾蒙治療、免疫治療) 83 圖二十:PEER檢體採檢計畫與檢體分析計畫 84 表一:2016年度台灣女性乳房原位癌主要分類與比例 85 表二:2016年度台灣女性乳癌主要分類與比例 86 表三:停經前荷爾蒙受體陽性轉移性乳癌的荷爾蒙治療 87 表四:整體存活的多變數分析 93 表五:乳癌專一存活時間的多變數分析(METABRIC Cohorts) 94 表六:藥物併用指數 95 表七:METABRIC的Discovery與Validation資料組基本特性 96 表八:PEER臨床試驗最佳反應 97 表九:腫瘤最佳反應、腫瘤未惡化存活期與不同時期荷爾蒙受體陽性比例 98 表十:免疫組織切片染色下的免疫細胞與腫瘤細胞的關係 99 附錄:在學期間著作 100 | |
dc.language.iso | zh-TW | |
dc.title | 優化停經前荷爾蒙受體陽性乳癌荷爾蒙治療:臨床前期實驗與臨床試驗 | zh_TW |
dc.title | Optimizing Hormonal Therapy in Premenopausal Estrogen Receptor Positive Breast Cancer: Preclinical Studies and Clinical Trials | en |
dc.type | Thesis | |
dc.date.schoolyear | 107-2 | |
dc.description.degree | 博士 | |
dc.contributor.coadvisor | 盧彥伸(Yen-Shen Lu) | |
dc.contributor.oralexamcommittee | 許駿(Chiun Hsu),曾令民,趙祖怡 | |
dc.subject.keyword | 荷爾蒙陽性乳癌,停經前乳癌,PI3K抑制劑,免疫治療, | zh_TW |
dc.subject.keyword | hormonal positive breast cancer,premenopausal breast cancer,PI3K inhibitor,immunotherapy, | en |
dc.relation.page | 101 | |
dc.identifier.doi | 10.6342/NTU201901046 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2019-07-01 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 腫瘤醫學研究所 | zh_TW |
顯示於系所單位: | 腫瘤醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-108-1.pdf 目前未授權公開取用 | 4.04 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。